A Phase 1/2 interventional study of BMS-986528 in Arthritis, Rheumatoid, sponsored by Bristol-Myers Squibb. Recruiting at 39 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Among 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb — 4 open to participants now, 8 under way, 2 of them phase 3. Arthritis, Rheumatoid · Bristol-Myers Squibb.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 38th largest by planned enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 1/2, and was the 91st registered.
3,334 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in India
Ages 18–65
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Belgium, France and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 15 · Phase 3 23 · Phase 4 2
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 121 across the 58 interventional studies, 917 across the 34 observational. Of the 82 that completed or were terminated, 31 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,560 studies on the registry; 117 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07171983Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat.
Exclusion Criteria
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Drug: BMS-986528
Specified dose on specified days
Number of participants with treatment-emergent adverse events (TEAEs)
Time frame: Up to Week 54
Number of participants with Serious Adverse Events (SAEs)
Time frame: Up to Week 54
Maximum observed concentration (Cmax)
Time frame: Up to Week 54
Time of maximum observed concentration (Tmax)
Time frame: Up to Week 54
area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to Week 54
Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to Week 54
Apparent terminal serum half-life (T-HALF)
Time frame: Up to Week 54
Apparent total body clearance (CLT/F)
Time frame: Up to Week 54
Apparent volume of distribution of terminal phase (Vz/F)
Time frame: Up to Week 54
Change from baseline in numbers and fractions of B cells
Time frame: Up to Week 54
Change from baseline in immunoglobulin G (igG) levels
Time frame: Up to Week 54
Change from baseline in igM levels
Time frame: Up to Week 54
Change from baseline in igE levels
Time frame: Up to Week 54
Change from baseline in igD levels
Time frame: Up to Week 54
Change from baseline in igA levels
Time frame: Up to Week 54
Number of participants with anti-drug antibody (ADA)
Time frame: Up to Week 54
Change from baseline in disease activity score 28-C-reactive protein (DAS28-CRP)
Time frame: At Week 12
Not enrolling at this site — choose another above.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Oct 2026 (actual). Primary completion is estimated for Oct 2029, 36 months after the start.
Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 36 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.